ReviewMast cells in renal inflammation and fibrosis: Lessons learnt from animal studies

- There is a considerable mast cell infiltrate in kidneys in renal inflammatory disease in humans.
- Examinations in mast cell or mast cell protease deficient mouse models are discussed.
- These reveal a highly contrasting picture with both beneficial and disease aggravating actions.
- Sometimes the action of mast cells differs from the one observed with a mast cell protease suggesting that mast cell mediators released at the same time can have opposite activities.

Mast cells are hematopoietic cells involved in inflammation and immunity and have been recognized also as important effector cells in kidney inflammation. In humans, only a few mast cells reside in kidneys constitutively but in progressive renal diseases their numbers increase substantially representing an essential part of the interstitial infiltrate of inflammatory cells. Recent data obtained in experimental animal models have emphasized a complex role of these cells and the mediators they release as they have been shown both to promote, but also to protect from disease and fibrosis development. Sometimes conflicting results have been reported in similar models suggesting a very narrow window between these activities depending on the pathophysiological context. Interestingly in mice, mast cell or mast cell mediator specific actions became also apparent in the absence of significant mast cell kidney infiltration supporting systemic or regional actions via draining lymph nodes or kidney capsules. Many of their activities rely on the capacity of mast cells to release, in a timely controlled manner, a wide range of inflammatory mediators, which can promote anti-inflammatory actions and repair activities that contribute to healing, but in some circumstances or in case of inappropriate regulation may also promote kidney disease.